Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/96051
Title:
Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
Authors:
Pettengell, Ruth; Crowther, Derek
Abstract:
Here we review the evidence that cytotoxic dose intensity is an important determinant of outcome in high- and intermediate-grade non-Hodgkin's lymphoma. The results of retrospective analyses and prospective studies support this proposition but confirmatory studies are required. We discuss the role of haemopoietic growth factors and mobilized peripheral blood progenitor cells to increase dose intensity. Studies using these modalities will enable the importance of dose intensity to be tested.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.
Citation:
Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. 1994, 5 Suppl 2:133-41 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
1994
URI:
http://hdl.handle.net/10541/96051
PubMed ID:
7911317
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPettengell, Ruthen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-04-08T16:24:51Z-
dc.date.available2010-04-08T16:24:51Z-
dc.date.issued1994-
dc.identifier.citationHaemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. 1994, 5 Suppl 2:133-41 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid7911317-
dc.identifier.urihttp://hdl.handle.net/10541/96051-
dc.description.abstractHere we review the evidence that cytotoxic dose intensity is an important determinant of outcome in high- and intermediate-grade non-Hodgkin's lymphoma. The results of retrospective analyses and prospective studies support this proposition but confirmatory studies are required. We discuss the role of haemopoietic growth factors and mobilized peripheral blood progenitor cells to increase dose intensity. Studies using these modalities will enable the importance of dose intensity to be tested.en
dc.language.isoenen
dc.subjectHaematopoietic Cell Growth Factorsen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBlood Component Transfusion-
dc.subject.meshBlood Transfusion, Autologous-
dc.subject.meshBone Marrow Diseases-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHematopoietic Cell Growth Factors-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHumans-
dc.subject.meshImmunologic Factors-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMulticenter Studies as Topic-
dc.subject.meshMultivariate Analysis-
dc.subject.meshPrognosis-
dc.subject.meshProspective Studies-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshRecombinant Proteins-
dc.subject.meshRemission Induction-
dc.subject.meshRetrospective Studies-
dc.subject.meshSalvage Therapy-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleHaemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.en
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.